Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fluconazole is a triazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This disrupts membrane integrity and function.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Treatment of vaginal candidiasis,Oropharyngeal and esophageal candidiasis,Candidal urinary tract infections, peritonitis, and systemic infections including candidemia, disseminated candidiasis, and pneumonia,Prophylaxis in bone marrow transplant recipients with chemotherapy or radiation therapy,Cryptococcal meningitis and cryptococcosis at other sites
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
400 mg IV on day 1, then 200 mg IV once daily
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
Terminal elimination half-life is approximately 30 hours (range 20–50 hours) in adults; prolonged in renal impairment. In neonates, half-life is longer (up to 90 hours).
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Fluconazole is primarily metabolized by the liver, with approximately 11% of the dose metabolized; the unchanged drug is the major circulating entity. Hepatic metabolism involves N-oxidation and glucuronidation, but specific CYP enzymes are not significantly involved. It is a moderate inhibitor of CYP2C9 and CYP3A4.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Primarily renal; approximately 80% of the dose is excreted unchanged in urine. Minor biliary/fecal elimination (<10%).
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
Approximately 11–12% bound to plasma proteins (mainly albumin).
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
Approximately 0.7 L/kg, indicating extensive distribution into total body water; penetrates well into tissues and CSF.
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
Oral bioavailability is >90% (virtually complete). IV administration is 100%.
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
For Cr Cl 50-90 m L/min: no adjustment; Cr Cl 10-49 m L/min: 50% dose or interval doubling; Cr Cl <10 m L/min (not on dialysis): 50% dose or interval doubling; on hemodialysis: one full dose after each dialysis session
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
No specific dose adjustment for Child-Pugh A or B; caution in severe hepatic impairment (Child-Pugh C) with monitoring
No dosage adjustment required for hepatic impairment.
Loading dose: 12 mg/kg IV (max 400 mg) on day 1, then 6 mg/kg IV (max 200 mg) once daily; for weight <40 kg, adjust based on weight using these mg/kg doses
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Dose based on renal function; no specific age-related adjustment beyond renal considerations
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
No FDA black box warning.
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
Hepatic toxicity: severe liver injury including fatal cases; discontinue if signs of liver disease develop,Anaphylaxis and allergic reactions,QT prolongation and torsade de pointes; use with caution in patients with proarrhythmic conditions,Adrenal insufficiency: fluconazole may inhibit adrenal steroidogenesis,Fetal harm: use during pregnancy only if benefit outweighs risk; multiple congenital anomalies reported,Skin reactions: monitoring for exfoliative disorders
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Hypersensitivity to fluconazole, azole antifungals, or any component of the formulation,Concomitant use with drugs that are CYP3A4 substrates with QT prolongation potential (e.g., cisapride, pimozide, quinidine, erythromycin, certain statins) due to risk of serious cardiac arrhythmias,Caution in patients with hepatic impairment, pregnancy, and breastfeeding
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
No significant food interactions with IV formulation. Oral fluconazole absorption is not affected by food. Avoid grapefruit juice? Not specifically contraindicated, but grapefruit juice may rarely affect CYP3A4 metabolism; no documented interaction with fluconazole.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
First trimester: Multiple case reports and epidemiological studies suggest an increased risk of spontaneous abortion and congenital anomalies, particularly craniofacial and skeletal malformations, with high-dose (400-800 mg/day) fluconazole exposure. Low-dose (150 mg single dose) exposure is not consistently associated with increased risk. Second and third trimesters: Standard doses are not associated with teratogenic risk, but prolonged high-dose therapy may increase risk of preterm birth and low birth weight.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Fluconazole is excreted into human breast milk with a milk-to-plasma ratio (M/P) of approximately 0.9-1.0. Concentrations in milk are similar to maternal plasma. After a single 150 mg dose, the infant dose is estimated at 2-3 mg/kg/day, which is less than the neonatal therapeutic dose. The American Academy of Pediatrics considers fluconazole compatible with breastfeeding, but caution is advised with prolonged high-dose therapy.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
Pregnancy does not significantly alter fluconazole pharmacokinetics; however, increased volume of distribution and enhanced clearance may occur, potentially requiring higher doses for severe infections. For systemic mycoses, standard dosing is generally used. For vaginal candidiasis, a single 150 mg oral dose is effective. For cryptococcal meningitis in pregnancy, recommended maintenance dose is 200-400 mg daily after loading dose (400 mg). Monitor therapeutic response and adjust dose based on clinical efficacy and local resistance patterns.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
DIFLUCAN (fluconazole) in 0.9% sodium chloride is an IV formulation for patients unable to take oral. Monitor renal function and adjust dose if Cr Cl <50 m L/min. Caution with hepatotoxic drugs; check LFTs. QTc prolongation risk: avoid with other QTc-prolonging agents and electrolyte abnormalities. Transition to oral fluconazole when feasible. Incompatible with amphotericin B and other drugs; use separate lines.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
Do not mix with other medications in the same IV line.,Report any signs of liver problems (yellowing skin/eyes, dark urine, severe nausea) or irregular heartbeat.,Complete the full course even if feeling better.,May cause dizziness; avoid driving if affected.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Fluconazole is a triazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This disrupts membrane integrity and function.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 400 mg IV on day 1, then 200 mg IV once daily. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. First trimester: Multiple case reports and epidemiological studies suggest an increased risk of spontaneous abortion and congenital anomalies, particularly craniofacial and skeleta. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.